{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:43:22Z","timestamp":1792014202476,"version":"4.4.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ctrv.2025.102941","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:00:13Z","timestamp":1744214413000},"page":"102941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Current and future directions in theranostics for neuroendocrine prostate cancer"],"prefix":"10.1016","volume":"136","author":[{"given":"Gokce","family":"Belge Bilgin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lucien-Matteoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadel A.","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep S.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungBaek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sounak","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2025.102941_b0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102941_b0010","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic Landscape of Neuroendocrine Prostate Cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10024","key":"10.1016\/j.ctrv.2025.102941_b0015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102941_b0020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102941_b0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102941_b0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102941_b0035","first-page":"273","article-title":"Neuroendocrine differentiation of prostate cancer: a review","volume":"2","author":"Parimi","year":"2014","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102941_b0040","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2025.102941_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00037","article-title":"Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?","volume":"5","author":"Grigore","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0050","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12885-017-3729-z","article-title":"Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma","volume":"17","author":"Tsai","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102941_b0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.humpath.2022.07.002","article-title":"De novo neuroendocrine features in prostate cancer","volume":"127","author":"Abdulfatah","year":"2022","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102941_b0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/his.14711","article-title":"WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer","volume":"81","author":"Kench","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2025.102941_b0065","article-title":"Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies","author":"Haffner","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41391-020-0214-6","article-title":"Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer","volume":"23","author":"Gupta","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0075","first-page":"26","article-title":"Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J Clin Transl Pathol"},{"issue":"S1","key":"10.1016\/j.ctrv.2025.102941_b0080","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1038\/modpathol.2017.164","article-title":"Neuroendocrine tumors of the prostate","volume":"31","author":"Fine","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102941_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2025.102941_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102941_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217068","article-title":"PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer","volume":"597","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102941_b0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2967\/jnumed.122.264741","article-title":"Is <sup>18<\/sup>F-FDG PET Needed to Assess <sup>177<\/sup>Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis","volume":"64","author":"Seifert","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102941_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-020-00640-2","article-title":"Neuron-specific enolase has potential value as a biomarker for [18F]FDG\/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients","volume":"10","author":"Rosar","year":"2020","journal-title":"EJNMMI Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102941_b0115","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0120","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00432-022-04061-7","article-title":"Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression","volume":"148","author":"Xie","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102941_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00814-2","article-title":"Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients","author":"Dasari","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102941_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pros.23715","article-title":"SRRM4 gene expression correlates with neuroendocrine prostate cancer","volume":"79","author":"Li","year":"2019","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102941_b0140","doi-asserted-by":"crossref","first-page":"13673","DOI":"10.3390\/ijms241813673","article-title":"Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer","volume":"24","author":"Zamora","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102941_b0145","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","article-title":"Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0150","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.7150\/thno.71788","article-title":"Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102941_b0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","article-title":"Role of FDG PET\/CT in Management of Patients with Prostate Cancer","volume":"54","author":"Sutherland","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102941_b0165","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.119.231068","article-title":"Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for (18)F-FDG Imaging of PSMA-Suppressed Tumors","volume":"61","author":"Bakht","year":"2020","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102941_b0170","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for (177)Lu-labelled PSMA Radioligand Therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"10276","key":"10.1016\/j.ctrv.2025.102941_b0175","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[<sup>177<\/sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102941_b0180","article-title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42(4_suppl):31-","author":"Pouliot","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1078-1439(01)00173-9","article-title":"Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines","volume":"7","author":"Dizeyi","year":"2002","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0190","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1464-410X.2010.09238.x","article-title":"Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer","volume":"106","author":"Morichetti","year":"2010","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102941_b0195","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pros.23426","article-title":"Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer","volume":"77","author":"Pedraza-Ar\u00e9valo","year":"2017","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102941_b0200","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-07-1494","article-title":"Identification of prognostic biomarkers for prostate cancer","volume":"14","author":"Kosari","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102941_b0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40336-022-00535-3","article-title":"SSTR-based theranostics in neuroendocrine prostate cancer (NEPC)","volume":"11","author":"Shahrokhi","year":"2023","journal-title":"Clinical and Translational Imaging"},{"issue":"Supplement 2","key":"10.1016\/j.ctrv.2025.102941_b0210","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.2967\/jnumed.116.186502","article-title":"Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine","volume":"58","author":"Levine","year":"2017","journal-title":"J Nucl Med"},{"issue":"3B","key":"10.1016\/j.ctrv.2025.102941_b0215","first-page":"2233","article-title":"Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients","volume":"26","author":"Mencoboni","year":"2006","journal-title":"Anticancer Res"},{"issue":"Supplement 2","key":"10.1016\/j.ctrv.2025.102941_b0220","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin Receptor Antagonists for Imaging and Therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2025.102941_b0225","article-title":"The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38(6_suppl):217-","author":"Bilen","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102941_b0230","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102941_b0235","first-page":"311","article-title":"Somatostatin receptor PET ligands - the next generation for clinical practice","volume":"8","author":"Pauwels","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102941_b0240","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/RLU.0000000000002824","article-title":"177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation","volume":"44","author":"Assadi","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102941_b0245","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003685","article-title":"Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA: A Chance for: 177: Lu-DOTATATE Therapy?","volume":"46","author":"Nesari Javan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ctrv.2025.102941_b0250","article-title":"Targeting DLL3 in neuroendocrine prostate cancer","volume":"16(6):330-","author":"Thoma","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"484","key":"10.1016\/j.ctrv.2025.102941_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2025.102941_b0260","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16(1):66","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2025.102941_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115065","article-title":"Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy","volume":"213","author":"Saalfeld","year":"2024","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102941_b0270","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/path.6063","article-title":"Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer","volume":"260","author":"Butler","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2025.102941_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2015.00012","article-title":"Introduction to Radiobiology of Targeted Radionuclide Therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Front Med"},{"key":"10.1016\/j.ctrv.2025.102941_b0285","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","author":"Steffin","year":"2024","journal-title":"Res Sq"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102941_b0290","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102941_b0295","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"K\u00f6rner","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0300","article-title":"Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"issue":"38","key":"10.1016\/j.ctrv.2025.102941_b0305","doi-asserted-by":"crossref","first-page":"61955","DOI":"10.18632\/oncotarget.11326","article-title":"Activation of GRP\/GRP-R signaling contributes to castration-resistant prostate cancer progression","volume":"7","author":"Qiao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.102941_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199432","article-title":"GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches","volume":"13","author":"Verhoeven","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102941_b0315","article-title":"Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis","volume":"1\u201312","author":"Belge Bilgin","year":"2024","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102941_b0320","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr Antagonist <sup>68<\/sup>Ga-SB3 PET\/CT Imaging of Primary Prostate Cancer in Therapy-Na\u00efve Patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102941_b0325","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","article-title":"Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102941_b0330","article-title":"A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"42(16_suppl):5066-","author":"Shakhnazaryan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102941_b0335","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102941_b0340","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0345","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","author":"Kesch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/genes13010135","article-title":"Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival","volume":"13","author":"Vlachostergios","year":"2022","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102941_b0355","article-title":"Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics","volume":"13","author":"Laudicella","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0360","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","article-title":"Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET\/CT","volume":"47","author":"Isik","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0365","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre) clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0370","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5\u2013SN38 Antibody\u2013drug Conjugate in Neuroendocrine Prostate Cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/ijo.2024.5615","article-title":"The emerging roles of CEACAM6 in human cancer (Review)","volume":"64","author":"Wu","year":"2024","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0385","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cas.13437","article-title":"Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression","volume":"109","author":"Rizeq","year":"2018","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0390","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2025.102941_b0395","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.123.267107","article-title":"CEACAM5-Targeted Immuno-PET in Androgen Receptor\u2013Negative Prostate Cancer","author":"Imberti","year":"2024","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102941_b0400","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","article-title":"B7-H3: a robust target for immunotherapy in prostate cancer","volume":"10","author":"Pulido","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2025.102941_b0405","article-title":"B7-H3\/CD276: An Emerging Cancer Immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.102941_b0410","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15(722):eadf6732","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102941_b0415","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with <sup>89<\/sup>Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102941_b0420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Feustel","year":"2024","journal-title":"Journal of Immunotherapy and Precision Oncology"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102941_b0425","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/carcin\/bgn226","article-title":"Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53\/p21-dependent pathway in human breast cancer cells","volume":"29","author":"Moh","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2025.102941_b0430","article-title":"Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma","author":"McColl","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102941_b0435","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2025.102941_b0440","article-title":"<strong>68Ga-TROP2-Nanobody for PET\/CT assessment of TROP2 expression in patients with various types of cancer<\/strong>","volume":"65(supplement 2)","author":"Chen","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102941_b0445","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/aja.2013.7","article-title":"Neuroendocrine differentiation of prostate cancer","volume":"15","author":"Li","year":"2013","journal-title":"Asian J Androl"},{"issue":"521","key":"10.1016\/j.ctrv.2025.102941_b0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0428","article-title":"Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102941_b0455","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1021\/acs.jmedchem.3c02285","article-title":"Development and Initial Characterization of the First (18)F-CXCR2-Targeting Radiotracer for PET Imaging of Neutrophils","volume":"67","author":"Spatz","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2025.102941_b0460","unstructured":"Castiglioni A. Identification of Ncam1 as a novel prognostic prostate cancer stem cell biomarker. 2022."},{"key":"10.1016\/j.ctrv.2025.102941_b0465","doi-asserted-by":"crossref","unstructured":"Williams SG, Yeang HA, Mitchell C, Caramia F, Byrne DJ, Fox SB, et al. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype. medRxiv. 2020:2020.06. 01.20115345.","DOI":"10.1101\/2020.06.01.20115345"},{"key":"10.1016\/j.ctrv.2025.102941_b0470","series-title":"CD56","first-page":"123","author":"Pettenon","year":"2022"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102941_b0475","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2967\/jnumed.114.152918","article-title":"In Vivo Imaging of Natural Killer Cell Trafficking in Tumors","volume":"56","author":"Galli","year":"2015","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102941_b0480","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2967\/jnumed.119.233163","article-title":"PET Imaging of the Natural Killer Cell Activation Receptor NKp30","volume":"61","author":"Shaffer","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2025.102941_b0485","doi-asserted-by":"crossref","unstructured":"Pham TT, Chenoweth A, Patel N, Banu A, Osborn G, Blower PJ, et al. InVivo PET Imaging of <sup>89<\/sup>Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody. Journal of Nuclear Medicine. 2024:jnumed.124.267876.","DOI":"10.2967\/jnumed.124.267876"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T10:29:01Z","timestamp":1746095341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":97,"alternative-id":["S0305737225000635"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102941","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future directions in theranostics for neuroendocrine prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102941"}}